European Platform for Chronic and Respiratory Diseases

World’s leader in allergy and clinical immunology

The Leader … 42 National Societies, more than 7000 academicians, researchers and clinicians

National societies GARD WHO EFA EAACI Patient Organizations committee EU Research Networks Predicta Medall EuroPrevall AllFUN Cohorts The Umbrella EAACI Dieticians EAACI GPs Allergy Nurses and other allied health JMA EAACI Mentorship Programme

Matrix Organization of Sections & IGs: The Matrix Allied health Epidemiology Junior Members Ocular allergy Allergy Diagnosis Functional genomics&proteomics Infection and allergy

Congresses The Quality

Allergy Impact factor: 6.2 PAI Impact factor: 2.7 EAACI newsletter EAACI monographs New EAACI E-Journal Clinical and Translational Allergy www.ctajournal.com

Food Quality & Safety Quality & Safety of Skin Care Products

EAACI Congress 2012, Geneva

The School

Bern-Interlaken Davos Dubrovnik Prague Rotterdam Davos Chalkidiki Antalya Oxford Bischenberg– Bischoffsheim Helsinki London Davos Venice Madeira Davos Norwich Fischbachau, Germany Mykonos, Greece Ancona, Italy EAACI Schools 2003-12 Berlin Sardinia Kusadasi Verona Saariselkä Krakow Athens Grainau Pickl Hannover Grainau äre Edinburgh Porto Heli, Greecei

Body surfaces: Skin 0.5% Mucosas 99.5% Lung: 100 m 2 Gut: 300 m 2 1 Ton food mixed with water per year 10 14 bacteria 1 kg 2000 species =12*0.6*60*24*365*80 3‘027‘456‘000 liters 10 billion particles (3 perLiter) 1 kg 1 1/2 Tennis court

Immune system is a highly interactive networking, which makes ist decisions on the basis of input from all organs and tissues, infections, normal flora bacteria, and many or even any environmental agents

Allergens Sensitization Phase IgE eosinophil mucosal epithelium Th2/Th0 apoptosis Effector Phase x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x

Las Meninas , 318x276 cm Prado Museum- Madrid 1656 , Diego Velàsquez

Pablo Picasso Las Meninas 161x129 cm Musée Picasso - Barcelone

Allergies as a global problem Age 13-14year Asher MI Lancet 2006,368,733-743
2 0-30% of world population suffer from allergies
High morbidity and may be life-threatening
Affect social life of patients
High economic impact of the society

What we do not know ?
R isk factors associated with development of allergy in various populations ( e.g rural vs. urban or children vs elderly)
Basic mechanism of development , persistence and progression ( e.g. role of infections)
Effective measures to prevent development and progression of allergies
Cost effective treatment modalities

Framework programmes – budget (in billion Euro)

CK-CARE Global Allergy Forum GAF-Davos Immunobiology of allergic inflammation WG4 C. Akdis, M. Akdis, K. Blaser, B. Bochner, E-M. de Villiers, A. Fire, S.Galli, G. Marone, M. Mempel, H. zur Hausen,

Research Problems
Causes of allergy are unknown
Reasons for recent increase in prevelance are unkown
Mechanisms of spontaneous resolution are unknown
Inadequate understanding of natural mechanisms that limit acute/chronic pathology
5. Marginal understanding of interactions among microbes, immune system and allergic disorders
6. Need for better subclassification of allergic disorders based on pathobiology
7. Need for agents to probe specific pathways in pathogenesis (seeking new therapeutic approaches)
8. Lack of approaches to prevent allergy
9. Need for better approaches to predict treatment responses and to monitor treatment effectiveness and disease activity
10. Need for better preclinical models (to address problems 1-9)

Allergy /Asthma in Research FP
In 1 - 6 FP allergy and asthma have not been listed as thematic priorities
The only relevant themes :
Food quality and safety
Environment
Life sciences, genomic and technology

Food allergy
Thirty years ago no one had ever heard of food allergies
Today 1-2% of adults and 4-8% of children suffer from food allergy
10 millions people in Europe
Reactions may be severe and life threatening
Management :
avoidance is difficult
n o effective prevention is available

Galenos (129 -201) the f irst physician: relationship between nose and lung

EU funding: 14,4 million € (5 years)
Global Allergy and Asthma European Network ( Network of Excellence)

GA²LEN Network of Excellence Collaboration centres Partners 26 partners 60 collaborating cente rs

Allergy in 7th FP ( 2007-2013)
MedAll – (2010 -2014) Mechanisms of development of allergy
FAST - 7 FP (2007-2012) New vaccines against food allergy: fish and fruits
Predicta – 7FP ( 2010-2015) Viral infections and allergy
Allergy 31 projects
Asthma 35 projects
13

2010 -2015 WP no. Work package WP 1 Longitudinal cohort WP 2 Mouse models WP 3 Epithelial models WP 4 Virus-bacteria interactions WP 5 Immune regulation WP 6 Resolution of inflammation WP 7 Diagnostics WP 8 Interventions WP 9 Management

Ted’s friends are laughing at him… He is the only one in the class without allergy !

Solution Networking & incentives for efficient collaborative research among clinicians, biologists/immunologists, epidemiologists and bioinformaticians, in collaborating groups elsewhere, to solve all of the unresolved questions Research, Research, Research Meet to discuss results

Solution Increase worldwide awareness and embrace all parties

Solution Develop evidence based One Health and (The Science of One Health)

Thank you

In 1st to 6 th FP allergy and asthma were not listed as them atic priorities
In 2001 EAACI open the office in Brussels
Task : lobbying for allergy themes in European FP

CK-CARE Action-I Induction of immune tolerance to allergens - Establish an immune tolerance subgroup Use direct approaches (tonsil, lymph node) Start clinical trials Detailed analyses of patients (e.g., deep sequencing of mRNAs and DNAs) Meet again to evaluate the data

CK-CARE Action-II A CK-CARE patient cohort should be established and a continuous flow of specimens should be provided (e.g., to CK-CARE network and collaborating outside laboratories) for broad „discovery“ research For endotypes/subtypes of asthma Identify endotypes (define biomarkers) Identify causative molecular mechanisms Clone and express biologicals Start clinical trials

Allergic diseases in 7 FP
« Allergy » was covered in the Food section of the 7th programme
EAACI and GA²LEN were raising awareness on the need to have « allergic diseases » in the Health theme
Meeting with the Rapporteur – prof. Jerzy Buzek February 2006
Presentation to the members of EP in Brussels -March 2006

EU Framework Programs
1984: First Framework Programme (1984-1987)
1987: SecondFramework Programme (1987-1991)
1990: Third Framework Programme (1990-1994)
1994: Fourth Framework Programme (1994-1998)
1998: FifthFramework Programme (1998-2002)
2000: European Research Area
2002: SixthFramework Programme (2002-2006)
2005: Proposal for the Seventh Framework Programme
2007: Seventh Framework Programme (2007-2013 )

Amendment 114 Annex I, Chapter I "Cooperation", Theme 1 "Health", Subtitle "Activities", bullet 2, indents 3 and 4
In the latest version of the FP7 framework text, “allergy” is proposed to be included under the Health theme , “Translating research for human health”, “Translational research in major diseases” as :
“ respiratory diseases, including those induced by allergies“.
Respiratory allergies in 7FP

BUT there are Geographic Differences There is v little allergy in Athens and NO reported allergy to peanut There is a lot of food allergy in Amsterdam to all the foods

But …improvement in managing food allergies needs data which have been lacking
How many people suffer from specific food allerg ies in Europe?
What are the risk factors/causes?
What is the impact on quality of life?
How much does food allergy cost to society?

European programme to stimulate research
7 Thematic priorities
Food Quality and Safety
Topic Allergy and asthma
Instruments T42 Allergy and asthma
Integrated Projects
Networks of Excellence
2002-2006

http://grforum.org	90
http://www.grforum.org	87
http://onehealth.grforum.org	29
http://www.idrc.info	3
http://idrc.info	2
http://onehealth.testing.grforum.net	2
http://131.253.14.250	1
http://www.onehealth.grforum.org	1

European Platform for Chronic and Respiratory Diseases

by Global Risk Forum GRFDavos

Accessibility

Categories

Upload Details

Usage Rights

8 Embeds 215

Statistics

European Platform for Chronic and Respiratory Diseases Presentation Transcript